sgmo-20220630
false2022Q20001001233--12-310000010012332022-01-012022-06-3000010012332022-08-01xbrli:shares00010012332022-06-30iso4217:USD00010012332021-12-3100010012332022-04-012022-06-3000010012332021-04-012021-06-3000010012332021-01-012021-06-30iso4217:USDxbrli:shares0001001233us-gaap:CommonStockMember2022-03-310001001233us-gaap:AdditionalPaidInCapitalMember2022-03-310001001233us-gaap:RetainedEarningsMember2022-03-310001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100010012332022-03-310001001233us-gaap:CommonStockMember2022-04-012022-06-300001001233us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001001233us-gaap:RetainedEarningsMember2022-04-012022-06-300001001233us-gaap:CommonStockMember2022-06-300001001233us-gaap:AdditionalPaidInCapitalMember2022-06-300001001233us-gaap:RetainedEarningsMember2022-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001001233us-gaap:CommonStockMember2021-12-310001001233us-gaap:AdditionalPaidInCapitalMember2021-12-310001001233us-gaap:RetainedEarningsMember2021-12-310001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001001233us-gaap:CommonStockMember2022-01-012022-06-300001001233us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001001233us-gaap:RetainedEarningsMember2022-01-012022-06-300001001233us-gaap:CommonStockMember2021-03-310001001233us-gaap:AdditionalPaidInCapitalMember2021-03-310001001233us-gaap:RetainedEarningsMember2021-03-310001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001001233us-gaap:NoncontrollingInterestMember2021-03-3100010012332021-03-310001001233us-gaap:CommonStockMember2021-04-012021-06-300001001233us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001001233us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001001233us-gaap:RetainedEarningsMember2021-04-012021-06-300001001233us-gaap:CommonStockMember2021-06-300001001233us-gaap:AdditionalPaidInCapitalMember2021-06-300001001233us-gaap:RetainedEarningsMember2021-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001001233us-gaap:NoncontrollingInterestMember2021-06-3000010012332021-06-300001001233us-gaap:CommonStockMember2020-12-310001001233us-gaap:AdditionalPaidInCapitalMember2020-12-310001001233us-gaap:RetainedEarningsMember2020-12-310001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001001233us-gaap:NoncontrollingInterestMember2020-12-3100010012332020-12-310001001233us-gaap:CommonStockMember2021-01-012021-06-300001001233us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001001233us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001001233us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001001233us-gaap:RetainedEarningsMember2021-01-012021-06-300001001233sgmo:AtTheMarketOfferingMember2022-01-012022-06-300001001233sgmo:AtTheMarketOfferingMember2021-01-012021-06-300001001233us-gaap:EmployeeStockMember2022-01-012022-06-300001001233us-gaap:EmployeeStockMember2021-01-012021-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-04-012022-06-30xbrli:pure0001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-04-012021-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-01-012022-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-01-012021-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:BiogenMAIncMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2022-04-012022-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:BiogenMAIncMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2021-04-012021-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:BiogenMAIncMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2022-01-012022-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:BiogenMAIncMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2021-01-012021-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:KitePharmaIncMember2022-04-012022-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:KitePharmaIncMember2021-04-012021-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:KitePharmaIncMember2022-01-012022-06-300001001233us-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMembersgmo:KitePharmaIncMember2021-01-012021-06-300001001233sgmo:SanofiMemberus-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2022-04-012022-06-300001001233sgmo:SanofiMemberus-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2021-04-012021-06-300001001233sgmo:SanofiMemberus-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2022-01-012022-06-300001001233sgmo:SanofiMemberus-gaap:RevenueFromContractWithCustomerMembersgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember2021-01-012021-06-300001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-06-300001001233us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-06-300001001233us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-06-300001001233us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001001233us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001001233us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001001233us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310001001233us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001001233us-gaap:MoneyMarketFundsMember2022-06-300001001233us-gaap:CommercialPaperMember2022-06-300001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-06-300001001233us-gaap:CashEquivalentsMember2022-06-300001001233us-gaap:CorporateDebtSecuritiesMember2022-06-300001001233us-gaap:AssetBackedSecuritiesMember2022-06-300001001233us-gaap:USTreasurySecuritiesMember2022-06-300001001233us-gaap:CertificatesOfDepositMember2022-06-300001001233us-gaap:MoneyMarketFundsMember2021-12-310001001233us-gaap:CashEquivalentsMember2021-12-310001001233us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310001001233us-gaap:CommercialPaperMember2021-12-310001001233us-gaap:CorporateDebtSecuritiesMember2021-12-310001001233us-gaap:AssetBackedSecuritiesMember2021-12-310001001233us-gaap:CertificatesOfDepositMember2021-12-310001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2020-08-012020-08-310001001233sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2020-07-272020-07-270001001233sgmo:AchievementOfCommercialMilestonesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2020-07-272020-07-270001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2020-07-272020-07-270001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2022-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2021-12-310001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-01-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-04-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-04-012021-06-300001001233us-gaap:LicenseAndServiceMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-01-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-01-012021-06-300001001233sgmo:ResearchServicesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-04-012022-06-300001001233sgmo:ResearchServicesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-04-012021-06-300001001233sgmo:ResearchServicesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-01-012022-06-300001001233sgmo:ResearchServicesMembersgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-01-012021-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMember2022-04-012022-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-04-012021-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMember2021-01-012021-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2021-01-012021-03-310001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2022-04-012022-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2022-01-012022-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2021-04-012021-06-300001001233sgmo:NovartisInstitutesForBioMedicalResearchIncMembersgmo:CollaborationAndLicenseAgreementMember2021-01-012021-06-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-04-012020-04-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-04-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2020-05-012020-05-310001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2020-04-300001001233sgmo:BiogenMAIncMembersgmo:PreApprovalMilestoneMembersgmo:CollaborationAndLicenseAgreementMember2020-04-300001001233sgmo:SalesBasedMilestoneMembersgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2020-04-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2020-04-012020-04-30sgmo:product_target0001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2022-06-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2021-12-310001001233sgmo:BiogenMAIncMember2022-01-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:BiogenMAIncMember2022-04-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:BiogenMAIncMember2021-04-012021-06-300001001233us-gaap:LicenseAndServiceMembersgmo:BiogenMAIncMember2022-01-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:BiogenMAIncMember2021-01-012021-06-300001001233sgmo:BiogenMAIncMembersgmo:ResearchServicesMember2022-04-012022-06-300001001233sgmo:BiogenMAIncMembersgmo:ResearchServicesMember2021-04-012021-06-300001001233sgmo:BiogenMAIncMembersgmo:ResearchServicesMember2022-01-012022-06-300001001233sgmo:BiogenMAIncMembersgmo:ResearchServicesMember2021-01-012021-06-300001001233sgmo:BiogenMAIncMember2022-04-012022-06-300001001233sgmo:BiogenMAIncMember2021-04-012021-06-300001001233sgmo:BiogenMAIncMember2021-01-012021-06-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2020-01-012020-12-310001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2021-01-012021-03-310001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2022-06-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2022-04-012022-06-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2022-01-012022-06-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2021-04-012021-06-300001001233sgmo:BiogenMAIncMembersgmo:CollaborationAndLicenseAgreementMember2021-01-012021-06-300001001233sgmo:BiogenMAIncMembersgmo:StockPurchaseAgreementMember2020-01-012020-12-310001001233sgmo:KitePharmaIncMembersgmo:CollaborationAndLicenseAgreementMember2018-04-012018-04-300001001233sgmo:KitePharmaIncMembersgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMembersgmo:CollaborationAndLicenseAgreementMember2018-04-012018-04-300001001233sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMembersgmo:KitePharmaIncMembersgmo:CollaborationAndLicenseAgreementMember2018-04-012018-04-30sgmo:milestonesgmo:option0001001233sgmo:KitePharmaIncMembersgmo:CollaborationAndLicenseAgreementMember2019-09-012019-09-300001001233sgmo:KitePharmaIncMembersgmo:CollaborationAndLicenseAgreementMember2022-06-300001001233sgmo:KitePharmaIncMembersgmo:CollaborationAndLicenseAgreementMember2021-12-310001001233sgmo:KitePharmaIncMember2022-01-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2022-04-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2021-04-012021-06-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2022-01-012022-06-300001001233us-gaap:LicenseAndServiceMembersgmo:KitePharmaIncMember2021-01-012021-06-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2022-04-012022-06-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2021-04-012021-06-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2022-01-012022-06-300001001233sgmo:ResearchServicesMembersgmo:KitePharmaIncMember2021-01-012021-06-300001001233sgmo:KitePharmaIncMember2022-04-012022-06-300001001233sgmo:KitePharmaIncMember2021-04-012021-06-300001001233sgmo:KitePharmaIncMember2021-01-012021-06-300001001233sgmo:SanofiMember2014-01-012014-01-31sgmo:program0001001233sgmo:SanofiMembersgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMembersgmo:CollaborationAndLicenseAgreementMember2014-01-012014-01-310001001233sgmo:SanofiMembersgmo:AchievementOfSpecifiedSalesMilestonesMembersgmo:CollaborationAndLicenseAgreementMember2014-01-012014-01-310001001233sgmo:SanofiMembersgmo:CollaborationAndLicenseAgreementMember2014-01-012014-01-310001001233sgmo:SanofiMember2022-06-300001001233sgmo:SanofiMembersgmo:MilestoneTwoMembersgmo:CollaborationAndLicenseAgreementMember2022-06-300001001233sgmo:SanofiMember2022-01-012022-06-30sgmo:product0001001233sgmo:SanofiMembersgmo:CollaborationAndLicenseAgreementMember2022-01-012022-06-300001001233sgmo:SanofiMembersgmo:MilestoneThreeMembersgmo:CollaborationAndLicenseAgreementMember2022-06-300001001233sgmo:SanofiMembersgmo:CollaborationAndLicenseAgreementMember2022-06-300001001233sgmo:SanofiMembersgmo:CollaborationAndLicenseAgreementMember2021-12-310001001233sgmo:SanofiMemberus-gaap:LicenseAndServiceMember2022-04-012022-06-300001001233sgmo:SanofiMemberus-gaap:LicenseAndServiceMember2021-04-012021-06-300001001233sgmo:SanofiMemberus-gaap:LicenseAndServiceMember2022-01-012022-06-300001001233sgmo:SanofiMemberus-gaap:LicenseAndServiceMember2021-01-012021-06-300001001233sgmo:SanofiMembersgmo:ResearchServicesMember2022-04-012022-06-300001001233sgmo:SanofiMembersgmo:ResearchServicesMember2021-04-012021-06-300001001233sgmo:SanofiMembersgmo:ResearchServicesMember2022-01-012022-06-300001001233sgmo:SanofiMembersgmo:ResearchServicesMember2021-01-012021-06-300001001233sgmo:SanofiMembersgmo:MilestoneAchievementMember2022-04-012022-06-300001001233sgmo:SanofiMembersgmo:MilestoneAchievementMember2021-04-012021-06-300001001233sgmo:SanofiMembersgmo:MilestoneAchievementMember2022-01-012022-06-300001001233sgmo:SanofiMembersgmo:MilestoneAchievementMember2021-01-012021-06-300001001233sgmo:SanofiMember2022-04-012022-06-300001001233sgmo:SanofiMember2021-04-012021-06-300001001233sgmo:SanofiMember2021-01-012021-06-300001001233sgmo:PfizerMember2017-05-012017-05-310001001233sgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMembersgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233sgmo:AchievementOfFirstCommercialSaleMilestonesMembersgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-012017-05-310001001233sgmo:PfizerMembersgmo:SBFiveTwoFiveAndOtherProductsMember2017-05-310001001233sgmo:PfizerMembersgmo:OtherProductsMember2017-05-310001001233sgmo:SBFiveTwoFiveAndOtherProductsMembersgmo:PfizerSB525Member2017-05-012022-03-310001001233sgmo:SBFiveTwoFiveAndOtherProductsMembersgmo:PfizerSB525Member2017-12-012022-03-310001001233sgmo:PfizerSB525Member2017-05-012017-05-310001001233sgmo:PfizerSB525Member2017-05-012022-03-310001001233sgmo:PfizerSB525Member2021-04-012021-06-300001001233sgmo:PfizerSB525Member2022-01-012022-06-300001001233sgmo:PfizerSB525Member2021-01-012021-06-300001001233sgmo:PfizerSB525Member2022-04-012022-06-300001001233sgmo:PfizerC9ORF72Member2017-12-012017-12-310001001233sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMembersrt:MaximumMembersgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2017-12-012017-12-310001001233sgmo:AchievementOfCommercialMilestonesMembersrt:MaximumMembersgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2017-12-012017-12-310001001233sgmo:PfizerC9ORF72Member2017-12-012022-03-310001001233sgmo:PfizerMembersgmo:CNineORFSevenTwoMember2017-12-012017-12-310001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2017-12-012017-12-310001001233sgmo:PfizerMembersgmo:CNineORFSevenTwoMember2020-01-012020-12-310001001233sgmo:PfizerMembersgmo:CNineORFSevenTwoMember2020-09-012020-09-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2022-04-012022-06-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2022-01-012022-06-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2021-01-012021-06-300001001233sgmo:CNineORFSevenTwoMembersgmo:PfizerC9ORF72Member2021-04-012021-06-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001001233us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001001233us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001001233sgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMember2020-08-012020-08-310001001233sgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMember2022-01-012022-06-300001001233sgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMember2022-04-012022-06-300001001233sgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMemberus-gaap:SubsequentEventMember2022-07-012022-07-310001001233sgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMember2021-04-012021-06-300001001233sgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMember2021-01-012021-06-300001001233us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembersgmo:JefferiesLLCMembersgmo:AtTheMarketOfferingAgreementMember2021-07-012021-07-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________
FORM 10-Q
________________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
Commission file number 000-30171
________________________________________________
SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________
Delaware68-0359556
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
  
7000 Marina Blvd., Brisbane, California, 94005
(Address of principal executive offices) (Zip Code)
(510) 970-6000
(Registrant’s telephone number, including area code)
________________________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareSGMONasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   ☐     No  
As of August 1, 2022, 156,553,107 shares of the issuer’s common stock, par value $0.01 per share, were outstanding.



Table of Contents
INDEX
SANGAMO THERAPEUTICS, INC.
Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to “Sangamo,” “the Company,” “we,” “us,” and “our” refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.
Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.
2

Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some statements contained in this report are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:
our strategy;
anticipated research and development of product candidates and potential commercialization of any resulting approved products;
the initiation, scope, rate of progress, enrollment, dosing, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;
the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;
the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and cell therapy technologies, zinc finger protein technology platform, zinc finger nucleases and zinc finger protein transcription factors;
our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including our ability to find a potential new collaboration partner for the BIVV003 (formerly known as SAR445136) program;
anticipated revenues from existing and new collaborations and the timing thereof;
our estimates regarding the impact of the evolving COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;
our research and development and other expenses;
our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers or from our own in-house manufacturing facilities;
the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates, including the ability to proceed with clinical trials following the imposition of regulatory holds or voluntary pauses on our clinical trials, and the timing and costs associated with obtaining regulatory approvals;
our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates;
competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet competition from rival products and product candidates;
our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;
our ability to manage the growth of our business;
our projected operating and financial performance;
our operational and legal risks; and
our plans, objectives, expectations and intentions and any other statements that are not historical facts.
3

Table of Contents
In some cases, you can identify forward-looking statements by use of future dates or by terms such as: “aim,” “anticipates,” “assume,” “believes,” “continues,” “could,” “estimates,” “expects,” “forecast,” “goal,” “guidance,” “intends,” “likely,” “may,” “objective,” “ongoing,” “plans,” “project,” “seeks,” “should,” “target,” “will,” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:
We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.
•    Many of our product candidates are based on novel zinc finger protein technologies that have yet to yield any approved commercially viable therapeutic products.
•    We have incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.
•    We require significant additional capital to fund our operations and continue operating as a viable business. This additional capital may not be available to us on favorable terms or at all.
•    We rely heavily on collaborations with larger biopharmaceutical companies to generate revenues and develop, obtain regulatory approvals for and commercialize many of our product candidates. If conflicts arise with our collaborators or if the collaborations terminate for any reason, our revenues and product development efforts would be negatively impacted.
•    Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.
•    Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We currently rely heavily on third‑party manufacturers and have limited experience manufacturing products ourselves. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.
•    Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.
•    We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.
•    Third parties, who may or may not be competitors, may allege that we are infringing, misappropriating, or otherwise practicing in an unauthorized manner their patents or other proprietary rights. Such allegations may result in infringement actions, other misappropriation actions or threats of such actions, all of which could increase the risks of costly, lengthy and distracting litigation with unpredictable results.
•    Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given that competition for these individuals is intense and increases in employee attrition across the United States resulting from the “great resignation.”
•    The ongoing and evolving COVID-19 pandemic could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners. If such impacts become material, our revenues and product development efforts could be negatively impacted.
•    The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock.
4

Table of Contents
Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on February 24, 2022, as supplemented by the risks described under “Risk Factors” in Part II, Item 1A of this Quarterly Report on Form 10-Q, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.
Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects.
This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even if we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
5

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM  1.    FINANCIAL STATEMENTS
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited; in thousands)
June 30,
2022
December 31,
2021
ASSETS
Current assets:
Cash and cash equivalents$117,705 $178,872 
Marketable securities198,017 197,676 
Interest receivable289 349 
Accounts receivable6,002 6,013 
Prepaid expenses and other current assets21,107 15,859 
Total current assets343,120 398,769 
Marketable securities, non-current47,966 88,169 
Property and equipment, net53,499 51,523 
Intangible assets49,529 53,760 
Goodwill36,702 39,702 
Operating lease right-of-use assets68,697 73,181 
Other non-current assets16,113 15,319 
Restricted cash1,500 1,500 
Total assets$617,126 $721,923 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$13,076 $9,759 
Accrued compensation and employee benefits13,913 20,840 
Other accrued liabilities14,204 11,577 
Deferred revenues78,794 85,711 
Total current liabilities119,987 127,887 
Deferred revenues, non-current129,921 166,776 
Long-term portion of lease liabilities41,530 44,055 
Deferred income tax6,122 6,645 
Other non-current liabilities1,285 1,217 
Total liabilities298,845 346,580 
Commitments and contingencies
Stockholders’ equity:
Preferred stock  
Common stock1,534 1,459 
Additional paid-in capital1,373,324 1,334,138 
Accumulated deficit(1,043,417)(956,267)
Accumulated other comprehensive loss(13,160)(3,987)
Total stockholders’ equity318,281 375,343 
Total liabilities and stockholders’ equity$617,126 $721,923 
See accompanying Notes to Condensed Consolidated Financial Statements.
6

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited; in thousands, except per share amounts)

Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Revenues$29,378 $27,872 $57,609 $54,152 
Operating expenses:
Research and development60,019 60,086 118,603 116,520 
General and administrative15,093 16,486 30,001 32,634 
Total operating expenses75,112 76,572 148,604 149,154 
Loss from operations(45,734)(48,700)(90,995)(95,002)
Interest and other income, net2,643 1,550 3,985 2,176 
Loss before income taxes(43,091)(47,150)(87,010)(92,826)
Income tax expense82 24 140 287 
Net loss(43,173)(47,174)(87,150)(93,113)
Net loss attributable to non-controlling interest (5) (11)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders$(43,173)$(47,169)$(87,150)$(93,102)
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders$(0.29)$(0.33)$(0.59)$(0.65)
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders148,158 143,984 147,194 143,550 
See accompanying Notes to Condensed Consolidated Financial Statements.
7

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited; in thousands)

Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Net loss$(43,173)$(47,174)$(87,150)$(93,113)
Foreign currency translation adjustment(6,108)1,308 (8,012)(3,441)
Net pension gains56  75  
Unrealized (loss) gain on marketable securities, net of tax(153)(35)(1,236)9 
Comprehensive loss(49,378)(45,901)(96,323)(96,545)
Comprehensive loss attributable to non-controlling interest (5) (11)
Comprehensive loss attributable to Sangamo Therapeutics, Inc.$(49,378)$(45,896)$(96,323)$(96,534)
See accompanying Notes to Condensed Consolidated Financial Statements.
8

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; in thousands, except share amounts)

Three Months Ended June 30, 2022
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
(Loss) Income
Total
Stockholders’
Equity
SharesAmount
Balances at March 31, 2022146,664,760 $1,467 $1,340,254 $(1,000,244)$(6,955)$334,522 
Issuance of common stock in connection with at-the-market offering, net of offering expenses6,228,666 62 24,212 — — 24,274 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax99,608 1 (171)— — (170)
Issuance of common stock under employee stock purchase plan359,468 4 1,111 — — 1,115 
Stock-based compensation— — 7,918 — — 7,918 
Foreign currency translation adjustment
— — — — (6,108)(6,108)
Net pension gains— — — — 56 56 
Net unrealized loss on marketable securities, net of tax— — — — (153)(153)
Net loss— — — (43,173)— (43,173)
Balances at June 30, 2022153,352,502 $1,534 $1,373,324 $(1,043,417)$(13,160)$318,281 

Six Months Ended June 30, 2022
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
(Loss) Income
Total
Stockholders’
Equity
SharesAmount
Balances at December 31, 2021145,921,530 $1,459 $1,334,138 $(956,267)$(3,987)$375,343 
Issuance of common stock in connection with at-the-market offering, net of offering expenses6,228,666 62 24,212 — — 24,274 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax842,838 9 (1,746)— — (1,737)
Issuance of common stock under employee stock purchase plan359,468 4 1,111 — — 1,115 
Stock-based compensation— — 15,609 — — 15,609 
Foreign currency translation adjustment
— — — — (8,012)(8,012)
Net pension gains— — — — 75 75 
Net unrealized loss on marketable securities, net of tax— — — — (1,236)(1,236)
Net loss— — — (87,150)— (87,150)
Balances at June 30, 2022153,352,502 $1,534 $1,373,324 $(1,043,417)$(13,160)$318,281 

9

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited; in thousands, except share amounts)
Three Months Ended June 30, 2021
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income (Loss)
Non-
Controlling
Interest
Total
Stockholders’
Equity
SharesAmount
Balances at March 31, 2021143,713,765 $1,437 $1,292,118 $(823,914)$714 $(938)$469,417 
Issuance of common stock in connection with at-the-market offering, net of offering expenses770,465 8 9,073 — — — 9,081 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax378,101 4 1,389 — — — 1,393 
Issuance of common stock under employee stock purchase plan244,570 2 2,052 — — — 2,054 
Stock-based compensation— — 9,483 — — — 9,483 
Acquisition of additional shares of Sangamo France— — (70)— — — (70)
Foreign currency translation adjustment
— — — — 1,308 — 1,308 
Net unrealized loss on marketable securities, net of tax— — — — (35)— (35)
Buy-out of non-controlling interest— — (943)— — 943 — 
Net loss— — — (47,169)— (5)(47,174)
Balances at June 30, 2021145,106,901 $1,451 $1,313,102 $(871,083)$1,987 $ $445,457 
Six Months Ended June 30, 2021
Common StockAdditional
Paid-in
Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income (Loss)
Non-
Controlling
Interest
Total
Stockholders’
Equity
SharesAmount
Balances at December 31, 2020142,063,203 $1,421 $1,269,375 $(777,981)$5,419 $(868)$497,366 
Issuance of common stock in connection with at-the-market offering, net of offering expenses1,805,227 18 24,714 — — — 24,732 
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax993,901 10 967 — — — 977 
Issuance of common stock under employee stock purchase plan244,570 2 2,052 — — — 2,054 
Stock-based compensation— — 17,007 — — — 17,007 
Acquisition of additional shares of Sangamo France— — (70)— — (64)(134)
Foreign currency translation adjustment
— — — — (3,441)— (3,441)
Net unrealized gain on marketable securities, net of tax— — — — 9 — 9 
Buy-out of non-controlling interest(943)943 — 
Net loss— — — (93,102)— (11)(93,113)
Balances at June 30, 2021145,106,901 $1,451 $1,313,102 $(871,083)$1,987 $ $445,457 
See accompanying Notes to Condensed Consolidated Financial Statements.
10

Table of Contents
SANGAMO THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited; in thousands)

Six Months Ended
June 30,
20222021
Operating Activities:
Net loss$(87,150)$(93,113)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization5,716 4,120 
Amortization of premium on marketable securities207 1,733 
Amortization and other changes in operating lease right-of-use assets4,225 4,067 
Gain on free shares (18)
Stock-based compensation15,609 17,007 
Net changes in operating assets and liabilities:
Interest receivable60 228 
Accounts receivable11 (1,658)
Prepaid expenses and other assets(4,992)(4,441)
Accounts payable and other accrued liabilities5,796 (3,204)
Accrued compensation and employee benefits(6,618)(3,253)
Deferred revenues(43,772)(41,481)
Lease liabilities(2,121)(2,102)
Other non-current liabilities69 998 
Net cash used in operating activities(112,960)(121,117)
Investing Activities:
Purchases of marketable securities(129,928)(180,049)
Maturities of marketable securities168,346 323,099 
Sales of marketable securities 6,870 
Purchases of property and equipment(8,284)(15,213)
Purchase of additional Sangamo France shares (119)
Net cash provided by investing activities30,134 134,588 
Financing Activities:
Proceeds from at-the-market offering, net of offering expenses21,929 22,223 
Taxes paid related to net share settlement of equity awards(1,827)(2,725)
Proceeds from exercise of stock options90 3,702 
Proceeds from issuance of common stock under employee stock purchase plan1,115 2,054 
Net cash provided by financing activities21,307 25,254 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash352 (176)
Net (decrease) increase in cash, cash equivalents, and restricted cash(61,167)38,549 
Cash, cash equivalents, and restricted cash, beginning of period180,372 132,829 
Cash, cash equivalents, and restricted cash, end of period$119,205 $171,378 
Supplemental cash flow disclosures:
Property and equipment included in unpaid liabilities$2,232 $2,267 
Right-of-use assets obtained in exchange for lease obligations$ $1,364 
Buy-out of non-controlling interest$ $943 
See accompanying Notes to Condensed Consolidated Financial Statements.
11

Table of Contents
SANGAMO THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1—ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization and Description of Business
Sangamo Therapeutics, Inc. (“Sangamo” or “the Company”) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.
Basis of Presentation
The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The Condensed Consolidated Balance Sheet data at December 31, 2021 was derived from the audited Consolidated Financial Statements included in Sangamo’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Annual Report”) as filed with the SEC on February 24, 2022.
The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.
The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December 31, 2021, included in the 2021 Annual Report.
Liquidity and Management’s Plan
Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents, and marketable securities as of June 30, 2022, and expected future milestones and research services revenue from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12 months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company’s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company’s stockholders, and any debt financing may include covenants that restrict the Company’s business.
Summary of Significant Accounting Policies
Use of Estimates
The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for
12

Table of Contents
making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Revenue Recognition
The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC Topic 606”). The Company’s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensees’ product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.
In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company’s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company’s current assumptions regarding the timing of its deliverables.
As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.
Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Novartis Institutes for BioMedical Research, Inc.37 %34 %34 %32 %
Biogen MA, Inc.34 %39 %37 %39 %
Kite Pharma, Inc.22 %23 %22 %23 %
Sanofi S.A.6 %3 %6 %4 %
13

Table of Contents
Funds received from the Company’s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.
Cash, Cash Equivalents, and Restricted Cash
Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5 million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.
A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
June 30,
2022
December 31,
2021
June 30,
2021
December 31,
2020
Cash and cash equivalents$117,705 $178,872 $169,878 $131,329 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows$119,205 $180,372 $171,378 $132,829 
Recently Adopted Accounting Pronouncements
None.
NOTE 2—FAIR VALUE MEASUREMENTS
The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities, and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).
14

Table of Contents
The fair value measurements of the Company’s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):
June 30, 2022
Fair Value Measurements
TotalLevel 1Level 2Level 3
Assets:
Cash equivalents:
Money market funds$39,669 $39,669 $ $ 
Commercial paper securities11,340  11,340  
Certificates of deposit2,498  2,498  
Total53,507 39,669 13,838  
Marketable securities:
U.S. government-sponsored entity debt securities26,425  26,425  
Commercial paper securities109,367  109,367  
Corporate debt securities10,806  10,806  
Asset-backed securities44,324  44,324  
U.S. treasury bills12,008  12,008  
Certificates of deposit43,054  43,054  
Total245,984  245,984  
Total cash equivalents and marketable securities$299,491 $39,669 $259,822 $ 
December 31, 2021
Fair Value Measurements
TotalLevel 1Level 2Level 3
Assets:
Cash equivalents:
Money market funds$119,919 $119,919 $ $ 
Total119,919 119,919   
Marketable securities:
U.S. government-sponsored entity debt securities30,614  30,614  
Commercial paper securities105,757  105,757  
Corporate debt securities33,682  33,682  
Asset-backed securities70,701  70,701  
Certificates of deposit45,091  45,091  
Total285,845  285,845  
Total cash equivalents and marketable securities$405,764 $119,919 $285,845 $ 
Cash Equivalents and Marketable Securities
The Company generally classifies its marketable securities as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.

15

Table of Contents
NOTE 3—CASH EQUIVALENTS AND MARKETABLE SECURITIES
The table below summarizes the Company’s cash equivalents and marketable securities (in thousands):
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Estimated
Fair Value
June 30, 2022
Assets
Cash equivalents:
Money market funds$39,669 $ $ $39,669 
Commercial paper securities11,340 2 (2)11,340 
Certificates of deposit2,498   2,498 
Total53,507 2 (2)53,507 
Marketable securities:
U.S. government-sponsored entity debt securities26,849  (424)26,425 
Commercial paper securities109,817 5 (455)109,367 
Corporate debt securities10,981  (175)10,806 
Asset-backed securities44,710  (386)44,324 
U.S. treasury bills12,008   12,008 
Certificate of deposits43,148 2 (96)43,054 
Total247,513 7 (1,536)245,984 
Total cash equivalents and marketable securities$301,020 $9 $(1,538)$299,491 
December 31, 2021
Assets
Cash equivalents:
Money market funds$119,919 $ $ $119,919 
Total119,919   119,919 
Marketable securities:
U.S. government-sponsored entity debt securities30,700 1 (87)30,614 
Commercial paper securities105,792 7 (42)105,757 
Corporate debt securities33,723 1 (42)33,682 
Asset-backed securities70,807 1 (107)70,701 
Certificate of deposits45,116 1 (26)